王曦

王曦，医学博士
罗彻斯特大学病理学系
601 Elmwood Ave. Box 626
Rochester, NY 14642
Phone: (585) 273-1802
医学董事会信息：2004年7月获取解剖病理学及临床病理学执业证

医学执照：纽约州医学注册，有效期内
专业方向：乳腺、GYN病理、软组织、骨病理及其他
个人兴趣：病理学诊断、病理教学、病理研究及翻译工作。
学术任职：
2010年8月至今，罗彻斯特大学药理实验室及病理学系副教授
2001年7月至2010年7月，罗彻斯特大学药理实验室及病理学系助理教授
教育经历：
1978年3月至1982年12月，中国广州，中山大学医学院获医学学士学位；
1986年9月至1989年8月，中国广州，中山大学医学院获医学硕士学位；

医学院毕业后医学教育经历：
2001年7月至2002年6月，纽约Memorial Sloan Kettering癌症中心，做肿瘤外科病理学的进修医生；
1997年11月至2001年6月，西弗吉尼亚州摩根敦，西弗吉尼亚大学医学院病理学系住院医师（解剖病理及临床病理）；
参加专业学术组织：
美国临床病理学会（ASCP）；
美加病理学会（USCAP）；
美国癌症研究学会（AACR）
管理经历：
2009年至今，罗彻斯特大学医学院政务会成员
Xi Wang, M.D.
Department of Pathology
University of Rochester
601 Elmwood Ave. Box 626
Rochester, NY 14642
Phone: (585) 273-1802

Academic appointment:
Aug. 2010 – Now Associate Professor, Department of Pathology and Lab Medicine, University of Rochester, NY
Jul. 2002 – Jul. 2010. Assistant Professor, Department of Pathology and Lab Medicine, University of Rochester, NY

Board certification:
Anatomic Pathology and Clinical Pathology, July, 2004

Licensure:
Medical License, State of New York: Active.

Education:
March 1978 – Dec. 1982: Bachelor of Medicine, Sun Yat-Sen University of Medical Sciences, Guangzhou, China.
September 1986 – Aug. 1989: Master of Medicine, Sun Yat-Sen University of Medical Sciences, Guangzhou, China.

Post Graduate Medical Education:
Jul. 2001 – Jun. 2002 Fellow of Oncology Surgical Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
 Nov. 1997 – Jun. 2001 Resident (AP and CP) of Dept. of Pathology, West Virginia University Hospital, Morgantown, WV

Professional Membership:
    - American Society of Clinical Pathology (ASCP)
    - United States and Canadian Academy of Pathology (USCAP)
    - American Association of Cancer Research (AACR)   
   
Administrative contribution:
    - Member of University of Rochester Medical Faculty Council 2009-Now

Education contributions – pathology residents
- Didactic Lectures:
- Soft tissue tumors – General introduction
- Soft tissue tumors – Immunohistochemistry in soft tissue tumors
- Soft tissue tumors – Lipomatous tumors
- Soft tissue tumors – Hypocellular/myxoid spindle cell tumors.
- Soft tissue tumors – Hypercellular spindle cell tumors.
- Soft tissue tumors – Small blue round cell tumors (2 lectures).
- Bone tumors.
- Endometrial biopsies/curetting.
- Introduction of ovarian tumors.
- Diagnostic problem in breast pathology.
- Case review conference
- Unknown Conference:
    - Soft tissue pathology
    - Bone pathology
    - GYN pathology
    - Endocrine pathology
    - Breast pathology
    - Pancreas pathology
- Frozen section diagnosis.

Education contributions – medical students:
    -  Lecturer:
- Bone pathology
- Diagnostic principles of surgical pathology in soft tissue tumors and tumor like lesions
    - Instructor:
- Breast pathology
     - GYN pathology
- Rheumatoid disease pathology

Institutional Lectures and Presentations:
-    Medical Oncology Grand Rounds, University of Rochester Medical Center, Invited Speaker: Some basics in breast pathology. 2007
-    Breast Center Grand Rounds, University of Rochester Medical Center:
o    Diagnostic problems in breast pathology. 2007
o    Papillary lesions of breast: diagnostic and management issues. 2009
o    Metaplastic breast carcinoma: pathological and clinical issues. 2010
o    DCIS and surgical margins. 2011
o    Breast papillary lesions revisit: is surgical excision necessary?2012
-    Breast Center Research Conference, University of Rochester Medical Center:
o    In searching of prognostic markers in breast carcinomas. 2008

Clinical Conference Contribution:
-    Breast multidisciplinary clinical conference, 2002 – Present;
-    Orthopedic multidisciplinary clinical conference, 2006 – Present;
-    Medical Oncology clinical conference, 2002 – Present;
-    OB-GYN clinical conference, 2009 – Present;

Research Experience:
Sep. 1996 - Nov. 1997 Research Associate, Harvard School of Public Health, Boston, MA
Nov. 1991 – Sep. 1996 Research Fellow, Harvard School of Public Health, Boston, MA
Aug. 1989 – Sep. 1991 Researcher, Cancer Institute, Guangzhou Medical College, P. R. China
Dec. 1982 - Aug. 1986 Teacher and Researcher, Dept. of Parasitology, Sun Yat-sen University of Medical Sciences, P. R. China
   
Publications:

Wang X, et al, The Expression of Alpha Tocopherol- Associated Protein (TAP) is Associated with Recurrence and Survival Rates of Node Positive Breast Cancer Patients. In writing.

Wang X, Hicks DG, et al, The co-expression of androgen receptor (AR) with estrogen receptor (ER) and the absence of AR activity in benign/normal breast luminal epithelium. Submitting.

Vella J, Rothburg P, Goldman B, diSant’Agnese PA, Wang X, Absence of MET mutation in multicentric papillary renal cell tumors in an allograft kidney. Submitting.

Li F; Wang X; Xu H; Roggli VL "Small Neuroendocrine Lesions in Intrathoracic Lymph Nodes of Patients With Primary Lung Adenocarcinoma: Real Metastasis?" The American Journal of Surgical Pathology. 34(1701-1707), 2010

Tang P, Wang J, Hicks DG, Wang X, Schiffhauer L, Lyman G, et al, A lower Allred score for Progesterone Receptor is strongly associated with a higher recurrence score of 21-gene assay in Breast Cancer. Cancer Investigation, 28(978-82), 2010

Johnykutty S, Tang P, Hicks DG, Wang X, Dual expression of ER and TAP in normal/benign breast epithelium and TAP down regulation in ER positive breast cancer. Modern Pathology 22 (770-775), 2009.

Wang X, Li J, Johnykutty S, Yeh SY, Reduced Expression of Tocopherol-Associated Protein (TAP/Sec14L2) in human breast cancer. Cancer Investigation, 27 (971-977), 2009.

Chen M, Wang X, Yeh SY, Radovick S, Generation and characterization of a complete null estrogen receptor mouse using Cre/LoxP technology. Molecular and Cellular Biochemistry 321 (145-153), 2009.

Simon R, Wang X, A46 XY Phenotypic female adolescent with bilateral gonadal tumors consisting of five different components. International Journal of Gynecological Pathology 27 (407-411), 2008

Tang P, Wang X, Schiffhauer L, Wang J, Bourne P, Yang Q, Quinn A, and Hajdu S, Expression Patterns of ER-a, PR, Her2/neu and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ. Annals of Clinical & Laboratory Science 36 (137-143), 2006

Tang P, Wang X, Schiffhauer L, Hajdu S, Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers. Annals of clinical & laboratory science 36 (16-22), 2006

Dupont J, Wang X, Soslow R, Wilms tumor gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using tissue microarrays. Gynecologic Oncology 94(449-455), 2004.

Wang X and Wenger SL, Multiple chromosome abnormalities following bone marrow transplant for chronic myelogenous leukemia. The Journal of the Association of Genetic Technologists 30 (1), 2004 

Wang X, Christiani DC, Mark EJ, Kelsey KT, Carcinogen exposure, p53 alteration and K-ras mutation in synchronous multiple primary lung cancers. Cancer 85 (1734-1739), 1998

Wang X, Egan KM, Gragoudas ES, Kelsey KT, Constitutional alterations in p16 in patients with uveal melanoma. Melanoma Research 6 (405-410), 1996

Kelsey KT, Nelson H, Wang X, Lung carcinogenesis: molecular and cellular mechanisms. Occupational Lung Disease. Thomson Science & Professional, 1997

Wang X, Christiani DC, Wiencke JK, Mark EJ, Kelsey KT, Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Cancer Epidemiology, Biomarkers &  Prevention. Vol. 4, 543-548, July/August 1995

 Xia F, Wang X, Yandell DW, Liber HL. Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer research Vol 55, 12-15, January 1, 1995

 Smith CM, Wang X, Hu H, and Kelsey KT, A polymorphism in the -aminolevulinic acid dehydratase gene may modify the pharmacokinetics and toxicity of lead. Environmental Health Perspectives. Vol. 103, 248-253, Mar. 1995

Platform presentation:
Wang X, Dupunt J, Soslow R, WT1 expression in ovarian and endometrial carcinomas using tissue microarrays. Annual Meeting of United States and Canadian Academy of Pathology (USCAP), 2003, Washington, DC

Poster presentations:
Xi Wang et al, The expression of Tocopherol Associated protein (TAP) is associated with recurrence and survival rates in node positive breast cancer Patients. USCAP 2011, San Antonio, TX

Joseph Weisensel, Xi Wang, Estrogen receptor (ER) and androgen receptor (AR) in normal human breast tissue and breast carcinoma. USCAP 2009, Boston, MA

Sharlin Johnykutty, Xi Wang, Spindle cell (sarcomatous) carcinoma of the breast: immunohistochemical profile and the clinical outcome. USCAP 2009, Boston, MA

Sharlin Johnykutty, Xi Wang, Dual expression of ER and TAP in human breast tissue and TAP down regulation in ER positive breast carcinoma. USCAP, Danver, CO, 2008

Sharlin Johnykutty, Xi Wang, Reduced TAP expression in human breast cancer. USCAP, San Diego, CA, 2007

 Xi Wang, et al, P53 mutational analysis indicating that small cell and non-small cell carcinoma of the lung have a common histogenesis. Eighty-eighth Annual Meeting of American Association for Cancer Research (AACR), San Diego, CA, 1997

Xi Wang, et al, p53 mutational status in lung cancer patients with multiple primary tumors. Eighty seventh Annual Meeting of AACR, Washington, DC, 1996

Xi Wang, et al, Polymorphism in carcinogen activating genes are associated with the absence of mutations in the p53 gene in lung cancer. Eighty- seventh Annual Meeting of AACR, Washington, DC, 1996

Xi Wang, et al, Mutations in the p53 gene in non-small cell lung cancer are associated with cigarette smoking and asbestos exposure. Eighty sixth Annual meeting of AACR, Toronto, Canada, 1995

Xi Wang, et al, The mutational spectra of p53 in human lung cancer. Eighty-fifth Annual Meeting of AACR, San Francisco, CA, 1994

Outline of research interests:
1. The role of TAP (Tocopherol Associated Protein) in hormonal carcinogenesis of breast cancer.
- TAP is a Vitamin E binding protein with tumor suppressor-like function. An antibody to TAP was produced in-house in Dr. Yeh’s lab.
- In the past a few years, we have shown that TAP is preferentially expressed in normal/benign breast luminal epithelial cells, similar to the pattern of expression of the estrogen receptor (ER), but its expression is down regulated in almost half (47%) of ER/PR positive breast carcinomas. This finding is not only the first report on TAP status in breast carcinomas, it is also unique, as other oncogenes or suppressor genes, such as p53 or Her2/neu, are altered mostly in ER/PR negative breast carcinomas.
- Currently, we are trying to determine if there is an association between TAP expression and clinical outcome. This is being performed using three approaches:
- Project 1: TAP expression in breast cancers of patients with stage IV disease and currently on Aromatase Inhibitor treatment alone. This project is in the data analysis stage.
- Project 2: Compare TAP expression status with the Oncotype score (derived by Oncotype using their proprietary analysis) in samples of primary tumors to determine if TAP has a similar or better predictive value for recurrence of disease. An abstract was submitted for presentation at the 2010 USCAP meeting.
- Project 3: TAP as a prognostic factor in a breast cancer cohort with 400 patients followed up for 10 years. This project is going on.

2. Steroid receptors in hormonal carcinogenesis of breast cancer.
- Breast cancer is a hormone-related cancer in which ER and PR status is a major determinant of clinical treatment. Although AR is strongly expressed in a high percentage of breast carcinomas, its role in breast carcinogenesis is not clear.
- Using dual immunohistochemical staining, we have found that AR is often co-expressed with ER in normal/benign breast luminal epithelial cells. This explains that breast carcinomas are mostly positive for both ER and AR.
- By immunohistochemical staining of consecutive sections from breast cancer blocks, we found that signaling proteins downstream of AR, such as PSA and GCDFP, are either negative or expressed in a pattern unrelated to AR expression in normal/benign breast luminal epithelial cells, indicating that AR is not functional in these cells.
- These findings may help to some degree to resolve the long-term debate regarding whether AR should be a target in the hormonal treatment of breast cancer.   
- One abstract is submitted for presentation at the 2010 USCAP meeting, and one paper is in preparation.